Inozyme Pharma Reports First Quarter 2025 Financial Results and Provides Business Highlights

- Interim data from ENERGY 3 trial highlight INZ-701’s potential to modify disease course in ENPP1 Deficiency, with sustained phosphate increases and favorable safety and immunogenicity profile to date -

Read more at globenewswire.com